July 26th 2025
A recent study reveals that many Americans neglect eye care due to cost and urgency misconceptions, despite the significant impact on daily life.
Post-ocular surgery, loteprednol delivers pain relief
June 1st 2010A post hoc analysis of data collected in two published, pivotal clinical trials demonstrates that in addition to its efficacy for treating inflammation following ocular surgery, loteprednol etabonate ophthalmic suspension 0.5% provides statistically significant relief of postoperative pain and other symptoms.
Read More
Moxifloxacin demonstrates prophylactic effectiveness
June 1st 2010In a quantitative determination of the prophylactic effectiveness of two commercially available ocular fluoroquiinolones within the anterior chamber of rabbit eyes, moxifloxacin ophthalmic solution 0.5% demonstrated significantly greater bacterial killing than besifloxacin ophthalmic suspension 0.6%.
Read More
Stronger gatifloxacin OK'd to address pathogen resistance
June 1st 2010The availability of a new formulation of gatifloxacin ophthalmic solution containing 0.5% active ingredient will provide ophthalmologists with a valuable option for addressing the growing problem of resistance among some important ocular pathogens.
Read More
Study: levofloxacin induced least toxicity, apoptosis
June 1st 2010In a study performed to evaluate and compare preserved versus unpreserved fluoroquinolone antibiotics, cell culture assays demonstrated some degree of toxicity and elevated induction of apoptosis in each of three commercially available topical ocular fluoroquinolone antibiotics.
Read More
Judge rejects CIBA Vision's attempt to block Johnson & Johnson contact lens sales
May 15th 2010J&J Vision Care may continue selling its Acuvue Oasys contact lenses even though their manufacturing infringes CIBA Vision's patent, in order to protect "millions of innocent contact lens wearers" who would have to be refitted with a different brand, a federal judge has ruled.
Read More
Device for treatment of diabetic macular edema provides controlled delivery
May 1st 2010Analyses of 24-month data from the two pivotal phase III trials investigating a proprietary fluocinolone acetonide-releasing intravitreal insert for the treatment of diabetic macular edema generated positive results that are the basis of filing a new drug application with the FDA.
Read More
Novel treatment related to age-related macular degeneration shows encouraging results
May 1st 2010Results from an interim analysis of a phase II study show fenretinide is well tolerated and exhibits promising biological activity in slowing lesion growth in patients with advanced geographic atrophy associated with age-related macular degeneration.
Read More